Abivax stock among SBF 120's strongest gainers, despite -11% over one month
The Paris-based biotech specialist in inflammatory diseases is regaining ground this Wednesday, posting a second rebound after several weeks of heavy selling pressure. The movement comes as the stock remains well below its moving averages and short positions, although declining sharply over one month, remain at elevated levels.
A rebound placing Abivax among SBF 120's strongest gainers, despite -11% over one month
Abivax advances 3.46% intraday to €86.75, ranking among SBF 120's strongest gainers. The rebound extends the one initiated the previous day, following a prolonged downturn that cost nearly 11% over one month. Over one year, however, the balance sheet remains largely positive at +22.4%, illustrating the amplitude of the stock's oscillations. The technical configuration remains under pressure.
The price is trading below its three moving averages: the 20-day MA at €92.75 represents a gap of 6.5%, the 50-day MA at €101.19 a gap of more than 14%, and the 200-day MA at €102.05 is at roughly the same distance level. The RSI at 30 is flirting with the oversold zone, a level that had already been reached in late September according to recent briefs. The support threshold at €81.45 remains the first floor to monitor in case of a turnaround, while the resistance at €103.30 represents the path to retrace to return to the moving averages.
Short positions decline by more than 2.5 points over one month, but remain elevated in the capital
Capital data testifies to a notable pullback in institutional bearish pressure: according to reported declarations, four funds cumulate 4.47% of capital sold short as of September 24, versus 7.05% one month earlier, a decline of 2.58 percentage points. This disengagement movement by short sellers indicates that certain operators have closed all or part of their positions, without one being able to infer a reversal of opinion on the security. The level remains above the threshold generally considered significant, signaling that funds remain positioned downward on the stock.
On the substance, the company had presented its first half 2026 financial results on September 21, posting an enlarged net loss and rising R&D expenses, in a phase of preparation for the regulatory filing of obefazimod expected by end of 2026. The company had then given itself financial visibility through the fourth quarter of 2029. This fundamental context remains the reference framework for the stock, in the absence of new corporate event to date.
